---
title: "JonesTrading Sticks to Its Hold Rating for Day One Biopharmaceuticals (DAWN)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281797417.md"
description: "JonesTrading analyst Soumit Roy has maintained a Hold rating on Day One Biopharmaceuticals (DAWN) with a price target of $21.50. The analyst consensus for the stock is also a Hold, with an average price target of $20.86. Roy specializes in the Healthcare sector and has an average return of -7.2% with a 32.22% success rate on his stock recommendations."
datetime: "2026-04-06T20:40:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281797417.md)
  - [en](https://longbridge.com/en/news/281797417.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281797417.md)
generator: "portal-rs"
---

# JonesTrading Sticks to Its Hold Rating for Day One Biopharmaceuticals (DAWN)

JonesTrading analyst Soumit Roy maintained a Hold rating on Day One Biopharmaceuticals today and set a price target of $21.50.

### Easter Sale - 70% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Roy covers the Healthcare sector, focusing on stocks such as CervoMed, Enliven Therapeutics, and Oric Pharmaceuticals. According to TipRanks, Roy has an average return of -7.2% and a 32.22% success rate on recommended stocks. 

Currently, the analyst consensus on Day One Biopharmaceuticals is a Hold with an average price target of $20.86.

### Related Stocks

- [DAWN.US](https://longbridge.com/en/quote/DAWN.US.md)

## Related News & Research

- [Algert Global LLC Buys 411,000 Shares of Day One Biopharmaceuticals, Inc. $DAWN](https://longbridge.com/en/news/279382687.md)
- [US families, healthcare providers under strain after Trump crackdown on Haitian immigrants](https://longbridge.com/en/news/296335867.md)
- [BLS data shows fastest-growing jobs through 2034 led by clean energy, healthcare, and tech](https://longbridge.com/en/news/296263775.md)
- [Visa, Lockheed Martin And A Health Care Stock On CNBC’s ‘Final Trades’](https://longbridge.com/en/news/296127265.md)
- [New Investors: 3 Rock-Solid Dividend Stocks to Build Your Portfolio Around](https://longbridge.com/en/news/296238006.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**